3-D Matrix, Ltd. announced that it expects to receive ¥12.8 million in funding from CVI Investments, Inc.
December 19, 2019
Share
3-D Matrix, Ltd. (JASDAQ:7777) announced that it will issue 40,000 23rd stock acquisition rights at ¥320 per stock acquisition right for gross proceeds of ¥12,800,000 on December 20, 2019. The transaction will include participation from returning investor CVI Investments, Inc. The company will receive the funding through third party allocation. Upon the exercise of the rights, the company will issue a maximum of 4,000,000 common shares. The minimum exercise price is ¥257. The securities issued in the transaction are subject to a hold period.
3-D Matrix, Ltd. is a company engaged in the research, development, manufacture and sale of medical products. The Company has Medical Product segment. The segment consists of two divisions. The medical product development and sales division is engaged in the research and development of medical equipment and drugs for surgery area, regeneration medicine area and drug delivery system (DDS) area based on the self-organizing peptide technology, including hemostatic, vascular embolization and alveolar bone reconstruction materials, among others. The research reagents sales division is engaged in the sale of medical products based on the self-organizing peptide technology for research and test use in universities and research institutes.
3-D MATRIX, LTD. 